Please login to the form below

lebrikizumab

This page shows the latest lebrikizumab news and features for those working in and with pharma, biotech and healthcare.

Dermira craters as acne drug fails late-stage test

Also in its pipeline is an injectable drug for atopic dermatitis - I L-13 inhibitor lebrikizumab - which was developed by Roche and licensed to Dermira in a deal valued at up ... That programme is in mid-stage clinical testing. Even if it successfully

Latest news

Setback for AZ as tralokinumab flunks asthma trial

The failure of tralokinumab hasn’t come out of the blue, as another trial (STRATOS 1) also failed to hit the mark, and other IL-13 inhibitors - including Roche’s lebrikizumab
Roche out-licenses lebrikizumab rights to Dermira

Roche out-licenses lebrikizumab rights to Dermira. Swiss drug maker stands to receive $80m upfront for the drug. ... Roche has opted to out-license the bulk of the rights to its IL-13 inhibitor lebrikizumab to dermatology company Dermira in a deal valued
AZ trial adds to pessimism about anti-IL-13 asthma drugs

It looks increasingly like a lost cause as AZ already reported disappointing phase IIb data with tralokinumab, and last year Roche reported disappointing results with its anti-IL-13 candidate lebrikizumab,
Teva gets EU nod for severe asthma drug Cinqaero

13 inhibitor lebrikizumab.
Roche shares slip as profits miss expectations

Aside with atezolizumab, Roche is also looking ahead to possible launches for multiple sclerosis candidate ocrelizumab - also due for filing shortly - as well as asthma drug lebrikizumab.

More from news
Approximately 2 fully matching, plus 10 partially matching documents found.

Latest Intelligence

Pharma deals during August 2014

This brings a much needed boost to its respiratory portfolio, which currently consists of Pulmozyme (cystic fibrosis) and Xolair (severe asthma) and products in clinical development, eg lebrikizumab (severe asthma).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Associate Director: £75, 000-90, 000

SAE – Healthcare PR – Award-Winning Consultancy: Salary TBC

Experienced Medical Writers: Competitive Salary and Benefits

Healthcare Communications Account Directors x 2: Salary TBC

Business Development Director – Health Education: excellent commission

Account Manager: Negotiable

Healthcare Advertising Senior Account Manager / AD / Senior AD: Salary TBC

Systematic Reviewer - Oxford: Negotiable

Senior Account Manager: Competitive Salary Offered

Medical (Scientific) Director: £120, 000 benefits

Account Manager / Account Director: Competative

Editorial Manager - MedComms: DOE

Principal Health Economist - North-West: Negotiable

Client Services Director – Medical Education Agency – North West...: Salary TBC

Senior Editorial Assistant – Greater Manchester: DOE

Senior Account Executive with progression to Account Manager, Me...: Excellent package

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Medical Writer: Bonus Scheme, PTO &Private Healthcare

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Account Executive/ Senior Account Executive: competitive Salary Offfered

Digital Communications Lead, Healthcare Brand and Medical Commun...: up to £50K

Account Director – Healthcare Marketing – Berks: Salary TBC

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?: What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma: Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies: Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...